tradingkey.logo
Markets
News
Analysis
Tools
Learn
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
tradingkey.logo

AstraZeneca PLC

AZN

77.960USD

+0.710+0.92%
Close 03/05, 16:00（ET）Quotes delayed by 15 min
241.76BMarket Cap
34.37P/E TTM

AstraZeneca PLC

77.960

+0.710+0.92%

Overview

Company

More Details of AstraZeneca PLC Company
Company Info
Company codeAZN
Company nameAstraZeneca PLC
IPO dateSep 21, 2007
Founded at1992
CEOMr. Marc Dunoyer
Number of employees94300
Security typeOrdinary Share
Fiscal year-endSep 21
Address1 Francis Crick Avenue
CityCAMBRIDGE
Stock exchangeLondon Stock Exchange
CountryUnited Kingdom
Postal codeCB2 0AA
Phone442073045000
Websitehttps://www.astrazeneca.com/
Company codeAZN
IPO dateSep 21, 2007
Founded at1992
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Ms. Deborah Disanzo Eldracher
Ms. Deborah Disanzo Eldracher
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Diana Layfield
Ms. Diana Layfield
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rene Haas
Mr. Rene Haas
Non-Executive Director
Non-Executive Director
--
--
Mr. Michel Demare
Mr. Michel Demare
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Revenue Breakdown
Currency: USDUpdate time: Wed, Mar 5
Currency: USDUpdate time: Wed, Mar 5
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Farxiga
7.65B
15.03%
Tagrisso
6.58B
12.91%
Imfinzi
4.71B
9.26%
Ultomiris
3.92B
7.70%
Calquenc
3.12B
6.14%
Other
24.93B
48.94%
By RegionUSD
Name
Revenue
Proportion
United States
21.80B
42.80%
China
6.41B
12.60%
United Kingdom
4.74B
9.30%
Other European Countries
3.66B
7.19%
Japan
3.45B
6.77%
Other
10.85B
21.31%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Farxiga
7.65B
15.03%
Tagrisso
6.58B
12.91%
Imfinzi
4.71B
9.26%
Ultomiris
3.92B
7.70%
Calquenc
3.12B
6.14%
Other
24.93B
48.94%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
PRIMECAP Management Company
1.32%
Capital International Investors
1.20%
Wellington Management Company, LLP
1.19%
T. Rowe Price Associates, Inc.
1.08%
T. Rowe Price International Ltd
0.85%
Other
94.32%
Shareholder Statistics
Shareholder
Proportion
PRIMECAP Management Company
1.32%
Capital International Investors
1.20%
Wellington Management Company, LLP
1.19%
T. Rowe Price Associates, Inc.
1.08%
T. Rowe Price International Ltd
0.85%
Other
94.32%
Type
Shareholder
Proportion
Investment Advisor
9.43%
Investment Advisor/Hedge Fund
6.01%
Hedge Fund
0.96%
Research Firm
0.88%
Bank and Trust
0.14%
Holding Company
0.07%
Pension Fund
0.04%
Venture Capital
0.02%
Family Office
0.01%
Other
82.39%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1935
545.66M
17.59%
+11.80M
2024Q4
1985
546.16M
17.61%
+11.21M
2024Q3
1920
519.94M
16.76%
-17.36M
2024Q2
1910
530.79M
17.12%
-10.50M
2024Q1
1865
523.00M
16.86%
-21.20M
2023Q4
1838
520.78M
16.79%
-27.27M
2023Q3
1815
530.16M
17.10%
-14.80M
2023Q2
1812
525.35M
16.94%
-28.73M
2023Q1
1803
534.30M
17.23%
-35.06M
2022Q4
1806
550.26M
17.75%
-33.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
PRIMECAP Management Company
41.01M
1.32%
-960.51K
-2.28%
Dec 31, 2024
Capital International Investors
37.50M
1.2%
+686.00K
+1.86%
Dec 31, 2024
Wellington Management Company, LLP
37.03M
1.19%
-208.19K
-0.55%
Dec 31, 2024
T. Rowe Price Associates, Inc.
33.74M
1.08%
-3.07M
-8.34%
Dec 31, 2024
T. Rowe Price International Ltd
26.60M
0.85%
+530.21K
+2.03%
Dec 31, 2024
Fidelity Management & Research Company LLC
18.14M
0.58%
-1.09M
-5.70%
Dec 31, 2024
Managed Account Advisors LLC
15.80M
0.5%
+7.65M
+93.93%
Dec 31, 2024
Jennison Associates LLC
15.43M
0.49%
+466.41K
+3.11%
Dec 31, 2024
Sanders Capital, LLC
15.18M
0.48%
+212.30K
+1.41%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
11.80M
0.38%
+233.78K
+2.01%
Dec 31, 2024
View more
Related ETFs
Update time: 14 hours ago
Update time: 14 hours ago
Name
Proportion
First Trust WCM International Equity ETF
5.11%
VanEck Pharmaceutical ETF
4.9%
Amplify Weight Loss Drug & Treatment ETF
4.51%
Roundhill GLP-1 & Weight Loss ETF
4.38%
ProShares Ultra Nasdaq Biotechnology
4.04%
Invesco Nasdaq Biotechnology ETF
3.82%
PGIM Jennison Focused Value ETF
3.4%
Franklin Genomic Advancements ETF
2.9%
Global X Aging Population ETF
2.77%
Amplify International Enhanced Dividend Income ETF
2.33%
View more
First Trust WCM International Equity ETF
Proportion5.11%
VanEck Pharmaceutical ETF
Proportion4.9%
Amplify Weight Loss Drug & Treatment ETF
Proportion4.51%
Roundhill GLP-1 & Weight Loss ETF
Proportion4.38%
ProShares Ultra Nasdaq Biotechnology
Proportion4.04%
Invesco Nasdaq Biotechnology ETF
Proportion3.82%
PGIM Jennison Focused Value ETF
Proportion3.4%
Franklin Genomic Advancements ETF
Proportion2.9%
Global X Aging Population ETF
Proportion2.77%
Amplify International Enhanced Dividend Income ETF
Proportion2.33%
Dividend
A total of 20.90B USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 06, 2025
AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Mar 24, 2025
Feb 21, 2025
Jul 25, 2024
AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024
Aug 09, 2024
Sep 09, 2024
Aug 09, 2024
Feb 08, 2024
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Mar 25, 2024
Feb 22, 2024
Jul 28, 2023
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023
Aug 11, 2023
Sep 11, 2023
Aug 10, 2023
Feb 10, 2023
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Mar 27, 2023
Feb 23, 2023
Aug 01, 2022
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022
Aug 12, 2022
Sep 12, 2022
Aug 11, 2022
Feb 10, 2022
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022
Feb 25, 2022
Mar 28, 2022
Feb 24, 2022
Aug 02, 2021
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021
Aug 13, 2021
Sep 13, 2021
Aug 12, 2021
Feb 11, 2021
AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021
Feb 26, 2021
Mar 29, 2021
Feb 25, 2021
Jul 30, 2020
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 14, 2020 going ex on Aug 13, 2020
Aug 14, 2020
Sep 14, 2020
Aug 13, 2020
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
tradingkey.logo
Markets
ForexCommoditiesCryptocurrenciesStocksETFs
News
AllEditors' PicksForexCommoditiesStocksIndicesCryptocurrenciesTechnical AnalysisEconomic IndicatorOther
Analysis
AllEditors' PicksEconomicsStocksForexCommoditiesCryptocurrenciesPolitics
Tools
Economic CalendarTrading StrategyInstitutional Data
Learn
Trading courses
About us
About TradingKeyExpert TeamContent CollaborationEditorial Policy
tradingkey.logo
Markets
News
Analysis
Tools
Learn
About us
Intraday Data provided by Refinitiv and subject to terms of use. Historical and current end-of-day data provided by Refinitiv. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy